|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
alborixin results in increased expression of BAX protein |
CTD |
PMID:27378626 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
alborixin results in decreased expression of BCL2 protein |
CTD |
PMID:27378626 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
increases cleavage |
EXP |
alborixin results in increased cleavage of CASP3 protein |
CTD |
PMID:27378626 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
increases activity |
EXP |
alborixin results in increased activity of CASP8 protein |
CTD |
PMID:27378626 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
increases activity |
EXP |
alborixin results in increased activity of CASP9 protein |
CTD |
PMID:27378626 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage |
EXP |
alborixin results in increased cleavage of PARP1 protein |
CTD |
PMID:27378626 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
|
G |
ACP5 |
acid phosphatase 5, tartrate resistant |
multiple interactions decreases expression |
ISO |
azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of ACP5 mRNA] azadirachtin results in decreased expression of ACP5 mRNA |
CTD |
PMID:31225646 |
|
NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993
|
|
G |
APAF1 |
apoptotic peptidase activating factor 1 |
increases expression |
EXP |
azadirachtin results in increased expression of APAF1 protein |
CTD |
PMID:20429769 |
|
NCBI chr12:98,645,290...98,735,433
Ensembl chr12:98,645,149...98,735,433
|
|
G |
BAD |
BCL2 associated agonist of cell death |
increases expression |
EXP |
azadirachtin results in increased expression of BAD mRNA |
CTD |
PMID:20429769 |
|
NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
azadirachtin results in increased expression of BAX mRNA |
CTD |
PMID:20429769 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
azadirachtin results in decreased expression of BCL2 mRNA; azadirachtin results in decreased expression of BCL2 protein |
CTD |
PMID:20429769 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
azadirachtin results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:20429769 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of BGLAP protein] |
CTD |
PMID:31225646 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
BID |
BH3 interacting domain death agonist |
increases expression |
EXP |
azadirachtin results in increased expression of BID mRNA |
CTD |
PMID:20429769 |
|
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
azadirachtin results in decreased expression of BIRC5 protein |
CTD |
PMID:20429769 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
azadirachtin results in increased expression of BMP2 mRNA; azadirachtin results in increased expression of BMP2 protein |
CTD |
PMID:31225646 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
CASP3 |
caspase 3 |
increases expression |
EXP |
azadirachtin results in increased expression of CASP3 mRNA; azadirachtin results in increased expression of CASP3 protein |
CTD |
PMID:20429769 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP6 |
caspase 6 |
increases expression |
EXP |
azadirachtin results in increased expression of CASP6 protein |
CTD |
PMID:20429769 |
|
NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583
|
|
G |
CASP8 |
caspase 8 |
increases expression |
EXP |
azadirachtin results in increased expression of CASP8 protein |
CTD |
PMID:20429769 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
increases expression |
EXP |
azadirachtin results in increased expression of CASP9 mRNA; azadirachtin results in increased expression of CASP9 protein |
CTD |
PMID:20429769 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
azadirachtin results in decreased expression of CCND1 mRNA |
CTD |
PMID:20429769 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
azadirachtin results in increased expression of CDKN1A mRNA; azadirachtin results in increased expression of CDKN1A protein |
CTD |
PMID:20429769 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization increases expression |
EXP |
azadirachtin affects the localization of CYCS protein azadirachtin results in increased expression of CYCS mRNA |
CTD |
PMID:20429769 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions affects binding increases expression |
ISO EXP |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [azadirachtin results in increased expression of ESR1 mRNA]; 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [azadirachtin results in increased expression of ESR1 protein]; azadirachtin inhibits the reaction [Estrogens deficiency results in decreased expression of ESR1 mRNA]; ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 mRNA]; ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 protein] azadirachtin binds to ESR1 protein azadirachtin results in increased expression of ESR1 mRNA; azadirachtin results in increased expression of ESR1 protein |
CTD |
PMID:31225646 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
increases expression multiple interactions affects binding |
ISO EXP |
azadirachtin results in increased expression of ESR2 mRNA; azadirachtin results in increased expression of ESR2 protein azadirachtin inhibits the reaction [Estrogens deficiency results in decreased expression of ESR2 mRNA] azadirachtin binds to ESR2 protein |
CTD |
PMID:31225646 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
decreases expression |
EXP |
azadirachtin results in decreased expression of IKBKB protein |
CTD |
PMID:20429769 |
|
NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
ISO |
azadirachtin results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31225646 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
ISO |
azadirachtin results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31225646 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
azadirachtin results in decreased expression of NFKB1 protein |
CTD |
PMID:20429769 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
decreases expression |
EXP |
azadirachtin results in decreased expression of NFKBIA protein modified form |
CTD |
PMID:20429769 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
PCNA |
proliferating cell nuclear antigen |
decreases expression |
EXP |
azadirachtin results in decreased expression of PCNA mRNA; azadirachtin results in decreased expression of PCNA protein |
CTD |
PMID:20429769 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
EXP |
azadirachtin results in decreased expression of RELA protein |
CTD |
PMID:20429769 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
ISO |
ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 mRNA]; ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 protein] azadirachtin results in increased expression of RUNX2 mRNA; azadirachtin results in increased expression of RUNX2 protein |
CTD |
PMID:31225646 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SMAD1 |
SMAD family member 1 |
increases expression |
ISO |
azadirachtin results in increased expression of SMAD1 protein modified form |
CTD |
PMID:31225646 |
|
NCBI chr 4:145,480,770...145,559,176
Ensembl chr 4:145,481,194...145,559,176
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
ISO |
azadirachtin results in decreased expression of TNF mRNA |
CTD |
PMID:31225646 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF11A |
TNF receptor superfamily member 11a |
decreases expression multiple interactions |
ISO |
azadirachtin results in decreased expression of TNFRSF11A mRNA azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of TNFRSF11A mRNA] |
CTD |
PMID:31225646 |
|
NCBI chr18:62,325,310...62,391,288
Ensembl chr18:62,325,287...62,391,288
|
|
G |
TP53 |
tumor protein p53 |
increases expression |
EXP |
azadirachtin results in increased expression of TP53 mRNA; azadirachtin results in increased expression of TP53 protein |
CTD |
PMID:20429769 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AIM2 |
absent in melanoma 2 |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of AIM2 protein |
CTD |
PMID:32645460 |
|
NCBI chr 1:159,055,051...159,147,132
Ensembl chr 1:159,056,129...159,187,843
|
|
G |
AKT1S1 |
AKT1 substrate 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:22689575 PMID:37914286 |
|
NCBI chr19:49,869,033...49,878,356
Ensembl chr19:49,869,033...49,878,459
|
|
G |
ALB |
albumin |
decreases uptake |
EXP |
bafilomycin A1 results in decreased uptake of ALB protein |
CTD |
PMID:16313995 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
APAF1 |
apoptotic peptidase activating factor 1 |
increases expression |
EXP |
bafilomycin A1 results in increased expression of APAF1 protein |
CTD |
PMID:28483490 |
|
NCBI chr12:98,645,290...98,735,433
Ensembl chr12:98,645,149...98,735,433
|
|
G |
APPL1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 3:57,227,729...57,273,471
Ensembl chr 3:57,227,726...57,278,105
|
|
G |
ARF6 |
ARF GTPase 6 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [maduramicin results in decreased expression of ARF6 protein] |
CTD |
PMID:37394175 |
|
NCBI chr14:49,893,082...49,897,054
Ensembl chr14:49,893,079...49,897,054
|
|
G |
ASIC1 |
acid sensing ion channel subunit 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Freund's Adjuvant results in increased expression of ASIC1 mRNA] |
CTD |
PMID:16769263 |
|
NCBI chr12:50,057,596...50,083,622
Ensembl chr12:50,057,548...50,083,611
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions |
EXP ISO |
ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] [bafilomycin A1 co-treated with Swainsonine] results in increased expression of ATG5 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of ATG5 protein |
CTD |
PMID:29938581 PMID:36402259 |
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] |
CTD |
PMID:12813466 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of BCL2 mRNA bafilomycin A1 promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein] |
CTD |
PMID:31310755 PMID:34374793 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BECN1 |
beclin 1 |
multiple interactions increases expression |
EXP ISO |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] [Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] bafilomycin A1 results in increased expression of BECN1 protein |
CTD |
PMID:32645460 PMID:33186601 PMID:33242459 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
BID |
BH3 interacting domain death agonist |
increases expression multiple interactions increases cleavage |
ISO EXP |
bafilomycin A1 results in increased expression of BID protein modified form vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein] |
CTD |
PMID:26853465 PMID:28378122 |
|
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
EXP |
bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] |
CTD |
PMID:25981168 PMID:26853465 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
CASP3 |
caspase 3 |
decreases activity increases cleavage multiple interactions increases activity |
EXP ISO |
bafilomycin A1 results in decreased activity of CASP3 protein bafilomycin A1 results in increased cleavage of CASP3 protein bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein] bafilomycin A1 results in increased activity of CASP3 protein [Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]; bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] [bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein] |
CTD |
PMID:20876807 PMID:23380477 PMID:24321340 PMID:24889822 PMID:25266202 PMID:25981168 PMID:26853465 PMID:28063998 PMID:28378122 PMID:29111403 PMID:30240709 PMID:32708634 PMID:33076330 PMID:33186601 PMID:34374793 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP4 |
caspase 4 |
increases activity |
EXP |
bafilomycin A1 results in increased activity of CASP4 protein |
CTD |
PMID:20371669 |
|
NCBI chr11:104,942,866...104,968,574
Ensembl chr11:104,942,866...104,969,366
|
|
G |
CASP7 |
caspase 7 |
increases activity decreases activity |
EXP |
bafilomycin A1 results in increased activity of CASP7 protein bafilomycin A1 results in decreased activity of CASP7 protein |
CTD |
PMID:20371669 PMID:25981168 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein] |
CTD |
PMID:28378122 PMID:29111403 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO EXP |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein] |
CTD |
PMID:28378122 PMID:30240709 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein] |
CTD |
PMID:33359579 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CDC25C |
cell division cycle 25C |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] |
CTD |
PMID:29074359 |
|
NCBI chr 5:138,285,265...138,338,355
Ensembl chr 5:138,285,269...138,338,355
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased expression of CDH1 protein] |
CTD |
PMID:36044967 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Capsaicin results in decreased expression of CDH2 protein] |
CTD |
PMID:36044967 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CTSB |
cathepsin B |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] |
CTD |
PMID:12813466 PMID:23380477 |
|
NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533
|
|
G |
CTSD |
cathepsin D |
decreases cleavage |
EXP |
bafilomycin A1 results in decreased cleavage of CTSD protein |
CTD |
PMID:36070022 |
|
NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573
|
|
G |
CTSL |
cathepsin L |
decreases cleavage |
EXP |
bafilomycin A1 results in decreased cleavage of CTSL protein |
CTD |
PMID:36070022 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:26682054 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
DDIT4 |
DNA damage inducible transcript 4 |
multiple interactions increases expression |
ISO |
[EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein bafilomycin A1 results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036
|
|
G |
DEPTOR |
DEP domain containing MTOR interacting protein |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:37914286 |
|
NCBI chr 8:119,873,722...120,050,918
Ensembl chr 8:119,873,717...120,050,918
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine] |
CTD |
PMID:22689575 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] |
CTD |
PMID:30237564 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
|
|
G |
EPOR |
erythropoietin receptor |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Aristolochic Acids results in increased degradation of and results in decreased expression of EPOR protein] |
CTD |
PMID:26136230 |
|
NCBI chr19:11,377,207...11,384,314
Ensembl chr19:11,377,207...11,384,342
|
|
G |
FASLG |
Fas ligand |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein] |
CTD |
PMID:20200208 PMID:28378122 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FMC1 |
formation of mitochondrial complex V assembly factor 1 homolog |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] |
CTD |
PMID:29371327 |
|
NCBI chr 7:139,340,472...139,346,328
Ensembl chr 7:139,339,457...139,346,328
|
|
G |
FOXO1 |
forkhead box O1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FTH1 |
ferritin heavy chain 1 |
multiple interactions |
EXP |
bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein] |
CTD |
PMID:37951334 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
FTL |
ferritin light chain |
multiple interactions |
EXP |
bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein] |
CTD |
PMID:37951334 |
|
NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,967,896
|
|
G |
GJA1 |
gap junction protein alpha 1 |
increases expression |
EXP |
bafilomycin A1 results in increased expression of GJA1 protein |
CTD |
PMID:35750204 |
|
NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
EXP |
bafilomycin A1 results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMOX1 |
heme oxygenase 1 |
decreases expression multiple interactions |
EXP |
bafilomycin A1 results in decreased expression of HMOX1 protein [bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein] |
CTD |
PMID:29796178 PMID:33076330 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
IFNG |
interferon gamma |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of IFNG mRNA |
CTD |
PMID:16932910 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL1B |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased expression of IL1B mRNA [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein] |
CTD |
PMID:16932910 PMID:24158569 PMID:32645460 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of IL6 mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS |
insulin |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
multiple interactions |
EXP |
bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:32283200 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
multiple interactions |
EXP |
bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] |
CTD |
PMID:35123989 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
LAMP1 |
lysosomal associated membrane protein 1 |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of LAMP1 protein [bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 protein |
CTD |
PMID:36402259 |
|
NCBI chr13:113,297,239...113,323,672
Ensembl chr13:113,297,239...113,323,672
|
|
G |
LCAT |
lecithin-cholesterol acyltransferase |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:32278738 |
|
NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131
|
|
G |
LRRK2 |
leucine rich repeat kinase 2 |
increases response to substance |
EXP |
LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 |
CTD |
PMID:25017139 |
|
NCBI chr12:40,224,997...40,369,285
Ensembl chr12:40,196,744...40,369,285
|
|
G |
MAN2A1 |
mannosidase alpha class 2A member 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Swainsonine results in decreased expression of MAN2A1 mRNA] |
CTD |
PMID:36402259 |
|
NCBI chr 5:109,689,927...109,869,625
Ensembl chr 5:109,689,927...109,869,625
|
|
G |
MAN2B1 |
mannosidase alpha class 2B member 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Swainsonine results in decreased expression of MAN2B1 mRNA] |
CTD |
PMID:36402259 |
|
NCBI chr19:12,646,512...12,666,742
Ensembl chr19:12,643,831...12,666,742
|
|
G |
MAP1LC3A |
microtubule associated protein 1 light chain 3 alpha |
multiple interactions increases expression |
ISO EXP |
bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of MAP1LC3A protein] bafilomycin A1 results in increased expression of MAP1LC3A protein modified form |
CTD |
PMID:30871063 PMID:31120128 PMID:37914286 |
|
NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases lipidation increases expression increases cleavage decreases degradation |
EXP ISO |
[bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ovatodiolide results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 results in increased expression of and results in increased lipidation of MAP1LC3B protein; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] bafilomycin A1 results in increased lipidation of MAP1LC3B protein [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] bafilomycin A1 results in increased expression of MAP1LC3B protein modified form [bafilomycin A1 co-treated with Swainsonine] results in increased expression of MAP1LC3B mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] bafilomycin A1 results in increased cleavage of MAP1LC3B protein bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:23880069 PMID:24145604 PMID:25301941 PMID:26459185 PMID:26853465 PMID:27305347 PMID:29248574 PMID:29524503 PMID:29908302 PMID:29938581 PMID:30209975 PMID:31310755 PMID:32278738 PMID:32525084 PMID:32981224 PMID:33124469 PMID:34580807 PMID:34634291 PMID:35149085 PMID:35472370 PMID:35872226 PMID:36070022 PMID:36402259 PMID:36639873 PMID:37678662 PMID:38000454 More...
|
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases expression |
EXP |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein] bafilomycin A1 results in increased expression of MAPK1 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases expression |
EXP |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein] bafilomycin A1 results in increased expression of MAPK3 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
bafilomycin A1 results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:31310755 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MLST8 |
MTOR associated protein, LST8 homolog |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:37914286 |
|
NCBI chr16:2,205,454...2,209,453
Ensembl chr16:2,204,248...2,209,453
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
bafilomycin A1 results in decreased phosphorylation of MTOR protein bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:31310755 PMID:37914286 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
increases expression |
EXP |
bafilomycin A1 results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
NCOA4 |
nuclear receptor coactivator 4 |
multiple interactions |
EXP |
bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein] |
CTD |
PMID:37951334 |
|
NCBI chr10:46,005,088...46,030,623
Ensembl chr10:46,005,088...46,030,623
|
|
G |
NDRG1 |
N-myc downstream regulated 1 |
multiple interactions |
EXP |
NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] |
CTD |
PMID:24532803 |
|
NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
EXP |
bafilomycin A1 results in increased expression of NFE2L2 protein bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein] |
CTD |
PMID:30698894 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions increases expression |
EXP |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein] bafilomycin A1 results in increased expression of NLRP3 protein |
CTD |
PMID:32645460 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108
|
|
G |
NR5A1 |
nuclear receptor subfamily 5 group A member 1 |
decreases expression |
EXP |
bafilomycin A1 results in decreased expression of NR5A1 protein |
CTD |
PMID:29524503 |
|
NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
EXP ISO |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein] bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] bafilomycin A1 results in increased expression of PARP1 protein modified form |
CTD |
PMID:20876807 PMID:21616090 PMID:24321340 PMID:25981168 PMID:28063998 PMID:29111403 PMID:31310755 PMID:34374793 PMID:35022897 More...
|
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of PCNA mRNA] |
CTD |
PMID:33359579 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PINK1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of PINK1 protein] |
CTD |
PMID:37914286 |
|
NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of PRKAA1 protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:37481222 PMID:37914286 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PRKAA2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of PRKAA2 protein] |
CTD |
PMID:37481222 |
|
NCBI chr 1:56,645,314...56,715,335
Ensembl chr 1:56,645,314...56,715,335
|
|
G |
PRKD2 |
protein kinase D2 |
multiple interactions |
EXP |
[PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]] which affects the abundance of Malondialdehyde; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1] |
CTD |
PMID:37951334 |
|
NCBI chr19:46,674,316...46,717,114
Ensembl chr19:46,674,275...46,717,127
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
bafilomycin A1 affects the localization of and results in increased activity of RELA protein |
CTD |
PMID:10339586 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:22689575 PMID:31310755 |
|
NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
|
|
G |
RPTOR |
regulatory associated protein of MTOR complex 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:37914286 |
|
NCBI chr17:80,544,838...80,966,368
Ensembl chr17:80,544,819...80,966,371
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC17A7 |
solute carrier family 17 member 7 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr19:49,429,401...49,441,527
Ensembl chr19:49,429,401...49,442,360
|
|
G |
SLC30A3 |
solute carrier family 30 member 3 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 2:27,253,684...27,275,817
Ensembl chr 2:27,253,684...27,275,817
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide] |
CTD |
PMID:26750564 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SNAI1 |
snail family transcriptional repressor 1 |
multiple interactions increases expression |
EXP |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein] bafilomycin A1 results in increased expression of SNAI1 protein |
CTD |
PMID:32645460 |
|
NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886
|
|
G |
SNCA |
synuclein alpha |
multiple interactions increases expression |
ISO |
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein bafilomycin A1 results in increased expression of SNCA protein |
CTD |
PMID:26031332 |
|
NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315
|
|
G |
SORT1 |
sortilin 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of SORT1 protein |
CTD |
PMID:25805502 |
|
NCBI chr 1:109,309,575...109,397,918
Ensembl chr 1:109,309,568...109,397,918
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions increases expression |
ISO EXP |
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of SQSTM1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; decamethrin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein] [Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] |
CTD |
PMID:21778691 PMID:21858812 PMID:23151917 PMID:24145604 PMID:24238063 PMID:24889822 PMID:25939952 PMID:25943029 PMID:26031332 PMID:27305347 PMID:28125038 PMID:29248574 PMID:29524503 PMID:30698894 PMID:32186374 PMID:32645460 PMID:32981224 PMID:33124469 PMID:33359579 PMID:34405320 PMID:34520793 PMID:34580807 PMID:35123989 PMID:36070022 PMID:36402259 PMID:37481222 More...
|
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
STK11 |
serine/threonine kinase 11 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of STK11 protein] |
CTD |
PMID:37481222 |
|
NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431
|
|
G |
TBK1 |
TANK binding kinase 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr12:64,452,120...64,502,114
Ensembl chr12:64,452,090...64,502,114
|
|
G |
TLR8 |
toll like receptor 8 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] |
CTD |
PMID:21398612 |
|
NCBI chr X:12,906,620...12,923,169
Ensembl chr X:12,906,620...12,923,169
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in increased expression of TNF mRNA [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] |
CTD |
PMID:16932910 PMID:24145604 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TOMM20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of TOMM20 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr 1:235,109,341...235,128,837
Ensembl chr 1:235,109,341...235,128,837
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] |
CTD |
PMID:23380477 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
ULK1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]] |
CTD |
PMID:29128638 |
|
NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150
|
|
G |
USP8 |
ubiquitin specific peptidase 8 |
multiple interactions |
EXP |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:35022897 |
|
NCBI chr15:50,424,405...50,514,421
Ensembl chr15:50,424,380...50,514,421
|
|
G |
VDAC1 |
voltage dependent anion channel 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr 5:133,971,871...134,114,540
Ensembl chr 5:133,971,871...134,004,975
|
|
G |
VDR |
vitamin D receptor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein |
CTD |
PMID:30698894 |
|
NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048
|
|
G |
VIM |
vimentin |
multiple interactions increases expression |
EXP |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein] bafilomycin A1 results in increased expression of VIM protein |
CTD |
PMID:32645460 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
|
G |
BIRC3 |
baculoviral IAP repeat containing 3 |
increases expression |
EXP |
bryostatin 1 results in increased expression of BIRC3 mRNA |
CTD |
PMID:14527959 |
|
NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403
|
|
G |
CD22 |
CD22 molecule |
increases expression |
EXP |
bryostatin 1 results in increased expression of CD22 protein |
CTD |
PMID:10741703 |
|
NCBI chr19:35,329,187...35,347,361
Ensembl chr19:35,319,261...35,347,361
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
multiple interactions |
EXP |
bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein] |
CTD |
PMID:10516758 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
EXP |
bryostatin 1 results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
IL10 |
interleukin 10 |
decreases expression |
EXP |
bryostatin 1 analog results in decreased expression of IL10 mRNA; bryostatin 1 results in decreased expression of IL10 mRNA |
CTD |
PMID:15614042 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12B |
interleukin 12B |
decreases expression increases expression |
EXP |
bryostatin 1 analog results in decreased expression of IL12B mRNA bryostatin 1 results in increased expression of IL12B mRNA |
CTD |
PMID:15614042 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
ITGAX |
integrin subunit alpha X |
increases expression |
EXP |
bryostatin 1 results in increased expression of ITGAX protein |
CTD |
PMID:10741703 |
|
NCBI chr16:31,355,176...31,382,999
Ensembl chr16:31,355,134...31,382,999
|
|
G |
PRKCA |
protein kinase C alpha |
multiple interactions decreases expression |
EXP |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCA protein bryostatin 1 results in decreased expression of PRKCA protein |
CTD |
PMID:8892972 |
|
NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
|
|
G |
PRKCB |
protein kinase C beta |
multiple interactions decreases expression |
EXP |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein; [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein alternative form bryostatin 1 results in decreased expression of PRKCB protein; bryostatin 1 results in decreased expression of PRKCB protein alternative form |
CTD |
PMID:8892972 |
|
NCBI chr16:23,835,983...24,220,611
Ensembl chr16:23,835,983...24,220,611
|
|
G |
PRKCG |
protein kinase C gamma |
multiple interactions decreases expression |
EXP |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCG protein bryostatin 1 results in decreased expression of PRKCG protein |
CTD |
PMID:8892972 |
|
NCBI chr19:53,881,094...53,907,652
Ensembl chr19:53,879,190...53,907,652
|
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
EXP |
bryostatin 2 results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased expression of BAX protein] |
CTD |
PMID:27742270 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
EXP |
concanamycin A results in increased expression of BNIP3 mRNA lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] |
CTD |
PMID:25981168 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal analog results in increased activity of CASP3 protein]; concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased activity of CASP3 protein] |
CTD |
PMID:27742270 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal analog results in increased activity of CASP9 protein]; concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased activity of CASP9 protein] |
CTD |
PMID:27742270 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
EXP |
concanamycin A results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
EXP |
concanamycin A results in increased expression of HIF1A protein lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
[lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein |
CTD |
PMID:25981168 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
|
G |
ACTB |
actin beta |
decreases response to substance |
EXP |
ACTB protein mutant form results in decreased susceptibility to latrunculin A |
CTD |
PMID:16685646 |
|
NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
|
|
G |
CASP3 |
caspase 3 |
increases activity |
EXP |
latrunculin A results in increased activity of CASP3 protein |
CTD |
PMID:16723733 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CDH1 |
cadherin 1 |
decreases uptake |
EXP |
latrunculin A results in decreased uptake of CDH1 protein modified form |
CTD |
PMID:20547569 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CTNNA1 |
catenin alpha 1 |
multiple interactions |
ISO |
latrunculin A affects the reaction [FSCN1 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]]; latrunculin A affects the reaction [FSCN2 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]] |
CTD |
PMID:27989596 |
|
NCBI chr 5:138,753,425...138,935,034
Ensembl chr 5:138,610,967...138,935,034
|
|
G |
DIAPH1 |
diaphanous related formin 1 |
affects localization |
ISO |
latrunculin A affects the localization of DIAPH1 protein |
CTD |
PMID:22918941 |
|
NCBI chr 5:141,515,021...141,619,000
Ensembl chr 5:141,515,016...141,619,055
|
|
G |
FSCN1 |
fascin actin-bundling protein 1 |
multiple interactions |
ISO |
latrunculin A affects the reaction [FSCN1 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]] |
CTD |
PMID:27989596 |
|
NCBI chr 7:5,592,816...5,606,655
Ensembl chr 7:5,592,816...5,606,655
|
|
G |
FSCN2 |
fascin actin-bundling protein 2, retinal |
multiple interactions |
ISO |
latrunculin A affects the reaction [FSCN2 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]] |
CTD |
PMID:27989596 |
|
NCBI chr17:81,515,062...81,537,130
Ensembl chr17:81,528,377...81,537,130
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP |
latrunculin A inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein]; latrunculin A inhibits the reaction [Uric Acid results in increased secretion of IL1B protein] |
CTD |
PMID:18403674 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
ITGB1 |
integrin subunit beta 1 |
decreases activity |
EXP |
latrunculin A results in decreased activity of ITGB1 protein |
CTD |
PMID:16723733 |
|
NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792
|
|
G |
PRLR |
prolactin receptor |
decreases uptake |
EXP |
latrunculin A results in decreased uptake of PRLR protein |
CTD |
PMID:20547569 |
|
NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487
|
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
latrunculin B inhibits the reaction [RHOA protein results in increased expression of ACTA2 mRNA] latrunculin B results in decreased expression of ACTA2 mRNA |
CTD |
PMID:11035001 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
AURKB |
aurora kinase B |
multiple interactions |
EXP |
latrunculin B inhibits the reaction [Silver results in increased phosphorylation of AURKB protein] |
CTD |
PMID:28499611 |
|
NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions |
ISO |
latrunculin B inhibits the reaction [Phenylephrine results in increased activity of GATA4 protein] |
CTD |
PMID:11739382 |
|
NCBI chr 8:11,676,935...11,760,002
Ensembl chr 8:11,676,959...11,760,002
|
|
G |
GDF15 |
growth differentiation factor 15 |
increases expression multiple interactions |
EXP |
latrunculin B results in increased expression of GDF15 mRNA; latrunculin B results in increased expression of GDF15 protein [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein] |
CTD |
PMID:23996089 |
|
NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] |
CTD |
PMID:12799187 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP ISO |
latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] jasplakinolide inhibits the reaction [latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein]]; latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:11502570 PMID:12799187 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
latrunculin B inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:11739382 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
latrunculin B inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11739382 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MYOD1 |
myogenic differentiation 1 |
decreases expression |
ISO |
latrunculin B results in decreased expression of MYOD1 protein |
CTD |
PMID:15252113 |
|
NCBI chr11:17,719,571...17,722,136
Ensembl chr11:17,719,571...17,722,136
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
[latrunculin B results in decreased activity of SRF protein] which results in increased expression of NOS2 protein; latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] jasplakinolide inhibits the reaction [latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein]]; latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:11502570 PMID:12799187 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
PPP1R9A |
protein phosphatase 1 regulatory subunit 9A |
affects localization |
ISO |
latrunculin B affects the localization of PPP1R9A protein |
CTD |
PMID:12052877 |
|
NCBI chr 7:94,907,236...95,296,415
Ensembl chr 7:94,907,202...95,296,415
|
|
G |
RHOA |
ras homolog family member A |
multiple interactions |
ISO |
latrunculin B inhibits the reaction [RHOA protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:11035001 |
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
SRF |
serum response factor |
multiple interactions decreases activity |
EXP |
[latrunculin B results in decreased activity of SRF protein] which results in increased expression of NOS2 protein |
CTD |
PMID:11502570 |
|
NCBI chr 6:43,171,269...43,181,506
Ensembl chr 6:43,171,269...43,181,506
|
|
G |
TAGLN |
transgelin |
decreases expression |
ISO |
latrunculin B results in decreased expression of TAGLN mRNA |
CTD |
PMID:11035001 |
|
NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] |
CTD |
PMID:12799187 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
EXP ISO |
Monensin inhibits the reaction [Ketamine results in decreased expression of and results in increased cleavage of APP protein] Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40)]; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42)] |
CTD |
PMID:35378374 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
ATP7A |
ATPase copper transporting alpha |
multiple interactions |
EXP |
Monensin inhibits the reaction [ATP7A protein affects the localization of Doxorubicin] |
CTD |
PMID:17510416 |
|
NCBI chr X:77,910,693...78,050,395
Ensembl chr X:77,910,690...78,050,395
|
|
G |
BACE1 |
beta-secretase 1 |
multiple interactions |
EXP |
Monensin inhibits the reaction [Ketamine results in increased expression of and affects the localization of BACE1 protein] |
CTD |
PMID:35378374 |
|
NCBI chr11:117,285,698...117,316,256
Ensembl chr11:117,285,232...117,316,259
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Monensin results in increased expression of BNIP3 protein |
CTD |
PMID:30718715 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity |
EXP |
Lithium inhibits the reaction [Monensin results in increased activity of CASP3 protein] |
CTD |
PMID:20799912 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions increases activity |
EXP |
Lithium inhibits the reaction [Monensin results in increased activity of CASP7 protein] |
CTD |
PMID:20799912 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions |
EXP |
Monensin inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Monensin inhibits the reaction [Quercetin results in increased secretion of CSF2 protein] |
CTD |
PMID:18346843 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
ISO |
[EGF protein co-treated with Monensin] results in increased expression of MYC mRNA |
CTD |
PMID:12632255 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
IL6 |
interleukin 6 |
decreases secretion |
EXP |
Monensin results in decreased secretion of IL6 protein |
CTD |
PMID:11216681 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
decreases degradation |
ISO |
Monensin results in decreased degradation of INS1 protein |
CTD |
PMID:2645939 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[EGF protein co-treated with Monensin] results in increased expression of MYC mRNA |
CTD |
PMID:12632255 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage |
EXP |
Monensin results in increased cleavage of PARP1 protein |
CTD |
PMID:30718715 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
SLC6A2 |
solute carrier family 6 member 2 |
multiple interactions |
EXP |
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]] |
CTD |
PMID:29908239 |
|
NCBI chr16:55,655,988...55,706,192
Ensembl chr16:55,655,988...55,707,645
|
|
G |
SLC6A3 |
solute carrier family 6 member 3 |
multiple interactions |
EXP |
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]] |
CTD |
PMID:29908239 |
|
NCBI chr 5:1,392,794...1,445,440
Ensembl chr 5:1,392,794...1,445,440
|
|
G |
SLC6A4 |
solute carrier family 6 member 4 |
multiple interactions |
EXP |
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]] |
CTD |
PMID:29908239 |
|
NCBI chr17:30,194,319...30,235,697
Ensembl chr17:30,194,319...30,236,002
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions |
EXP |
Monensin inhibits the reaction [SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide] |
CTD |
PMID:26750564 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
TRPM2 |
transient receptor potential cation channel subfamily M member 2 |
decreases expression increases expression multiple interactions |
EXP |
Monensin results in decreased expression of TRPM2 protein alternative form Monensin results in increased expression of TRPM2 protein alternative form Lithium inhibits the reaction [Monensin results in increased expression of TRPM2 protein alternative form] |
CTD |
PMID:20799912 |
|
NCBI chr21:44,353,621...44,442,644
Ensembl chr21:44,350,163...44,443,081
|
|
G |
ZEB1 |
zinc finger E-box binding homeobox 1 |
increases response to substance |
EXP |
ZEB1 protein results in increased susceptibility to Monensin |
CTD |
PMID:30718715 |
|
NCBI chr10:31,318,417...31,529,804
Ensembl chr10:31,318,495...31,529,814
|
|
|
G |
ALB |
albumin |
multiple interactions |
EXP |
oridonin binds to and affects the folding of ALB protein |
CTD |
PMID:25816984 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX mRNA]; oridonin inhibits the reaction [Kainic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
EXP ISO |
oridonin analog results in decreased expression of BCL2 protein; oridonin results in decreased expression of BCL2 protein oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA]; oridonin inhibits the reaction [Kainic Acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:16019488 PMID:31430510 PMID:31594861 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
oridonin analog results in decreased expression of BIRC5 protein |
CTD |
PMID:31594861 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
CASP3 |
caspase 3 |
increases cleavage multiple interactions |
EXP ISO |
oridonin results in increased cleavage of CASP3 protein oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; oridonin inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:16019488 PMID:31430510 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of CAT protein]; oridonin inhibits the reaction [Kainic Acid results in decreased activity of CAT protein] |
CTD |
PMID:31430510 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
oridonin analog results in decreased expression of CCND1 protein |
CTD |
PMID:31594861 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CDH1 |
cadherin 1 |
increases expression multiple interactions |
EXP |
oridonin results in increased expression of CDH1 mRNA; oridonin results in increased expression of CDH1 protein oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein] |
CTD |
PMID:30243739 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH2 |
cadherin 2 |
decreases expression multiple interactions |
EXP |
oridonin results in decreased expression of CDH2 mRNA; oridonin results in decreased expression of CDH2 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 protein] |
CTD |
PMID:30243739 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
oridonin analog inhibits the reaction [EGF protein promotes the reaction [EGFR protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein promotes the reaction [SRC protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
oridonin analog inhibits the reaction [EGF protein promotes the reaction [EGFR protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGFR protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
GLUL |
glutamate-ammonia ligase |
multiple interactions |
ISO |
oridonin inhibits the reaction [Kainic Acid results in decreased expression of GLUL mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr 1:182,378,098...182,391,790
Ensembl chr 1:182,378,098...182,392,206
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of GSR protein]; oridonin inhibits the reaction [Kainic Acid results in decreased activity of GSR protein] |
CTD |
PMID:31430510 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
oridonin results in increased expression of HMOX1 mRNA; oridonin results in increased expression of HMOX1 protein oridonin results in increased expression of and results in increased activity of HMOX1 protein |
CTD |
PMID:18351433 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
IFNG |
interferon gamma |
decreases expression multiple interactions |
ISO EXP |
oridonin results in decreased expression of IFNG protein oridonin analog inhibits the reaction [IFNG protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:18351433 PMID:31594861 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL10 |
interleukin 10 |
increases expression |
ISO |
oridonin results in increased expression of IL10 protein |
CTD |
PMID:18351433 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL1B protein] |
CTD |
PMID:31430510 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2 |
interleukin 2 |
decreases expression |
ISO |
oridonin results in decreased expression of IL2 protein |
CTD |
PMID:18351433 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL6 protein] oridonin analog inhibits the reaction [IL6 protein affects the localization of STAT3 protein]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [JAK1 protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT1 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT3 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein results in increased expression of STAT3 mRNA]; oridonin analog inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31430510 PMID:31594861 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
IMPDH2 |
inosine monophosphate dehydrogenase 2 |
decreases activity |
EXP |
oridonin results in decreased activity of IMPDH2 protein |
CTD |
PMID:37871880 |
|
NCBI chr 3:49,024,325...49,029,398
Ensembl chr 3:49,024,325...49,029,447
|
|
G |
JAK1 |
Janus kinase 1 |
multiple interactions |
EXP |
oridonin analog inhibits the reaction [IL6 protein promotes the reaction [JAK1 protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [JAK1 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr 1:64,833,229...65,067,746
Ensembl chr 1:64,833,223...65,067,754
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
oridonin analog results in decreased expression of MKI67 protein |
CTD |
PMID:31594861 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
decreases expression |
EXP |
oridonin analog results in decreased expression of MMP2 protein |
CTD |
PMID:31594861 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
oridonin analog results in decreased expression of MMP9 protein |
CTD |
PMID:31594861 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
oridonin analog results in decreased expression of MYC protein |
CTD |
PMID:31594861 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
EXP |
oridonin results in increased cleavage of PARP1 protein oridonin analog results in decreased expression of and results in increased cleavage of PARP1 protein |
CTD |
PMID:16019488 PMID:31594861 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of PTGS2 protein] |
CTD |
PMID:31430510 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RANGAP1 |
Ran GTPase activating protein 1 |
multiple interactions |
EXP |
oridonin results in decreased expression of and affects the localization of RANGAP1 protein |
CTD |
PMID:25746355 |
|
NCBI chr22:41,244,779...41,302,369
Ensembl chr22:41,244,779...41,286,187
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions |
EXP |
oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:30243739 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMAD3 |
SMAD family member 3 |
multiple interactions |
EXP |
oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:30243739 |
|
NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173
|
|
G |
SNAI1 |
snail family transcriptional repressor 1 |
decreases expression multiple interactions |
EXP |
oridonin results in decreased expression of SNAI1 mRNA; oridonin results in decreased expression of SNAI1 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 protein] |
CTD |
PMID:30243739 |
|
NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886
|
|
G |
SNAI2 |
snail family transcriptional repressor 2 |
decreases expression multiple interactions |
EXP |
oridonin results in decreased expression of SNAI2 mRNA; oridonin results in decreased expression of SNAI2 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 protein] |
CTD |
PMID:30243739 |
|
NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
oridonin analog inhibits the reaction [EGF protein promotes the reaction [SRC protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT1 protein binds to STAT3 protein]] |
CTD |
PMID:31594861 |
|
NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
oridonin analog results in decreased phosphorylation of STAT3 protein oridonin analog binds to and results in decreased stability of STAT3 protein; oridonin analog inhibits the reaction [EGF protein promotes the reaction [EGFR protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein promotes the reaction [SRC protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [EGFR protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [IFNG protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [IL6 protein affects the localization of STAT3 protein]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [JAK1 protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT1 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT3 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein results in increased expression of STAT3 mRNA]; oridonin analog inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [JAK1 protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
increases expression multiple interactions |
ISO EXP |
oridonin results in increased expression of TGFB1 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 protein]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 protein]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 protein]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM protein]; oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]; oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:18351433 PMID:30243739 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TH |
tyrosine hydroxylase |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of TNF protein] |
CTD |
PMID:31430510 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
VIM |
vimentin |
multiple interactions decreases expression |
EXP |
oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM protein] oridonin results in decreased expression of VIM mRNA; oridonin results in decreased expression of VIM protein |
CTD |
PMID:30243739 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of BAX mRNA |
CTD |
PMID:32795494 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2L11 |
BCL2 like 11 |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of BCL2L11 mRNA |
CTD |
PMID:32795494 |
|
NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
[Ryanodine co-treated with Thioctic Acid] results in decreased activity of CASP3 protein; Ryanodine inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] |
CTD |
PMID:17079870 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
[bastadin 12 co-treated with Ryanodine co-treated with Dizocilpine Maleate] inhibits the reaction [tetrabromobisphenol A results in decreased activity of CAT protein] |
CTD |
PMID:27718046 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Ryanodine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:21113126 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CXCL2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of CXCL2 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of DDIT3 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
FASLG |
Fas ligand |
multiple interactions |
ISO |
Ryanodine inhibits the reaction [FASL protein affects the localization of Calcium] |
CTD |
PMID:20200208 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FKBP1A |
FKBP prolyl isomerase 1A |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of FKBP1A mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr20:1,368,978...1,393,054
Ensembl chr20:1,368,977...1,393,164
|
|
G |
FKBP1B |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of FKBP1B mRNA; Ryanodine inhibits the reaction [FKBP1B gene mutant form inhibits the reaction [Acetylcholine affects the localization of and affects the abundance of Calcium]] |
CTD |
PMID:17261647 PMID:32795494 |
|
NCBI chr 2:24,033,206...24,063,681
Ensembl chr 2:24,049,701...24,063,681
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of GPT protein] |
CTD |
PMID:32795494 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of HMOX1 mRNA |
CTD |
PMID:32795494 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HOMER1 |
homer scaffold protein 1 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of HOMER1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 5:79,372,636...79,514,134
Ensembl chr 5:79,372,636...79,514,134
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of IL1B mRNA |
CTD |
PMID:32795494 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of ITGAM mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
NR4A1 |
nuclear receptor subfamily 4 group A member 1 |
multiple interactions |
ISO |
NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 protein] |
CTD |
PMID:23183170 |
|
NCBI chr12:52,022,832...52,059,503
Ensembl chr12:52,022,832...52,059,507
|
|
G |
PLAU |
plasminogen activator, urokinase |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Mustard Gas results in increased activity of PLAU protein] |
CTD |
PMID:9101041 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
RYR1 |
ryanodine receptor 1 |
multiple interactions |
EXP ISO |
Triclosan promotes the reaction [Ryanodine binds to RYR1 protein] 2,3,6,2',3',6'-hexachlorobiphenyl affects the reaction [Ryanodine binds to RYR1 protein]; chlorantranilipole promotes the reaction [Ryanodine binds to RYR1 protein]; flubendiamide promotes the reaction [Ryanodine binds to RYR1 protein] |
CTD |
PMID:18795164 PMID:18954145 PMID:30329129 |
|
NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273
|
|
G |
RYR2 |
ryanodine receptor 2 |
affects binding multiple interactions |
ISO |
Ryanodine binds to RYR2 protein decamethrin promotes the reaction [Ryanodine binds to RYR2 protein] 2,3,6,2',3',6'-hexachlorobiphenyl affects the reaction [Ryanodine binds to RYR2 protein] |
CTD |
PMID:11278295 PMID:18954145 PMID:31166131 |
|
NCBI chr 1:237,042,184...237,833,988
Ensembl chr 1:237,042,184...237,833,988
|
|
G |
S100A8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of S100A8 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of S100A9 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein] |
CTD |
PMID:23183170 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of TNF mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of VCAM1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|